|
|
|
|
||
Re: Nobody? Just maybe Precigen is the outlier in this instance. Isn't that the kind of situation you might look to invest in. I think even psuedo Stanford GSB's know that comparison is an important, if not the most important, component of valuation. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
37773 | Re: Nobody? | Mabel | 0 | 1/21/2020 9:13:36 AM |